# Alcresta Therapeutics, Inc.

- Location (FDA's records): Waltham, MA
- FDA decisions: 7 (2016–2025): 7 510(k) clearances
- Product codes: PLQ (7)
- Predicates its devices cite: 10 (7 its own); citations of its devices by later devices: 7 (7 its own)
- Recalls linked to its devices: 0 (0 Class I)
- Data: FDA decisions to Oct 25, 2026; recalls to Oct 12, 2026

## Firms whose devices it cites most
- Alcresta, Inc.: 3 (https://510kreport.com/company/alcresta)

## Its most-cited devices
- K161247: Relizorb (2016), cited by 2
- K163057: Relizorb (2017), cited by 1
- K232784: RELiZORB® (2023), cited by 1
- K191379: RELiZORB (2019), cited by 1
- K243284: RELiZORB (100300/ 100301) (2025), cited by 1
- K231156: Enzyme Packed Cartridge - RELiZORB (2023), cited by 1

## Recent decisions
- K250499: RELiZORB (100300/100301) (Apr 17, 2025)
- K243284: RELiZORB (100300/ 100301) (Jan 15, 2025)
- K232784: RELiZORB® (Dec 21, 2023)
- K231156: Enzyme Packed Cartridge - RELiZORB (Aug 30, 2023)
- K191379: RELiZORB (Dec 4, 2019)
- K163057: Relizorb (Jul 12, 2017)
- K161247: Relizorb (Jun 30, 2016)

Source page: https://510kreport.com/company/alcresta-therapeutics